Product information
- Pharmaceutical class : Tyrosine kinase inhibitor (TKI)
- Active compound : Brigatinib
- Indications:
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
- Available dosages & packagings :
Alunbrig Starter Pack 90 mg + 180 mg (90 mg: 1 x 7 tablets + 180 mg: 1 x 21 tablets)
Alunbrig 30mg (1 x 28 tablets)
Alunbrig 90mg (1 x 28 tablets)
Alunbrig 180mg (1 x 28 tablets)
- Posology and dosing
The recommended starting dose of Alunbrig is 90 mg once daily for the first 7 days, then 180 mg once daily. Treatment should continue as long as clinical benefit is observed.
Dosing interruption and/or dose reduction may be required based on individual safety and tolerability as explained in Table 1 of the Summary of Product characteristics.
Alunbrig is for oral use. The tablets should be swallowed whole, with water, taken with or without food.
- Price list and reimbursement conditions:
Click here to view the Alunbrig prices, product codes and reimbursement conditions for Belgium.
Publications: Link to the ALTA 1L 2nd interim Analysis
Publications: Link to ALTA 1L Final results
Camidge DR, et al., ALTA 1L- Final Analysis, J Thoracic Oncol. 2021. Volume 16, Issue 12: P2091-2108
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section “Undesirable effects” for how to report adverse reactions.
C-APROM/BE/ALUN/0047